Use of Cardiac Allografts With Mild and Moderate Left Ventricular Hypertrophy Can Be Safely Used in Heart Transplantation to Expand the Donor Pool

Journal of the American College of Cardiology

Volumn 51, Issue 12, 2008, Pages 1214-1220

  Goland, Sorel ^b   Czer, Lawrence S C ^a   Kass, Robert M ^a   Siegel, Robert J ^a   Mirocha, James ^a   De Robertis, Michele A ^a   Lee, Jason ^a   Raissi, Sharo ^a   Cheng, Wen ^a   Fontana, Gregory ^a   Trento, Alfredo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b KAPLAN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART GRAFT; HEART LEFT VENTRICLE HYPERTROPHY; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ECHOCARDIOGRAPHY; FEMALE; HEART TRANSPLANTATION; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 40749104890     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.11.052     Document Type: Article

References (22)

1. Gridelli B., and Remuzzi G. Strategies for making more organs available for transplantation. N Engl J Med 343 (2000) 404-410
2. Costanzo M.R., Augustine S., Bourge R., et al. Selection and treatment of candidates for heart transplantation: a statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 92 (1995) 3593-3612
3. 1999 Annual Report of the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data 1989-1998 (1999), HHS/GRSA/OSP/DOT and United Network for Organ Sharing, Richmond, VA
4. Sweeney M.S., Lammermeier D.E., Frazier O.H., et al. Extension of donor criteria in cardiac transplantation: surgical risk versus supply-side economics. Ann Thorac Surg 50 (1990) 7-10
5. Jeevanandam V., Furukawa S., Prendergast T.W., et al. Standard criteria for an acceptable donor heart are restricting heart transplantation. Ann Thorac Surg 62 (1996) 1268-1275
6. Zaroff J.G., Rosengard B.R., Armstrong W.F., et al. Consensus conference report. Maximizing use of organs recovered from the cadaver donor: cardiac recommendations. Circulation 106 (2002) 836-841
7. Laks H., Marelli D., Fazio D., et al. Intermediate term results of the alternate recipient list for heart transplantation. J Heart Lung Transplant 19 (2000) 39
8. Marelli D., Laks H., Fazio D., Moore S., Moriguchi J., and Kobashigawa J. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant 19 (2000) 496-503
9. Aziz S., Soine L.A., Lewis S.L., et al. Donor left ventricular hypertrophy increases risk for early graft failure. Transpl Int 10 (1997) 446-450
10. Goland S., Czer L.S., Kass R.M., et al. Pre-existing pulmonary hypertension in patients with end-stage heart failure: impact on clinical outcome and hemodynamic follow-up after orthotopic heart transplantation. J Heart Lung Transplant 26 (2007) 312-318
11. Lang R.M., Bierig M., Devereux R.B., et al., Chamber Quantification Writing Group, American Society of Echocardiography's Guidelines and Standards Committee, European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
12. Trulock E.P., Edwards L.B., Taylor D.O., Boucek M.M., Keck B.M., and Hertz M.I. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 24 (2005) 956-967
13. Czerska B., Stewart R.W., Hobbs R.E., et al. Hypertension and left ventricular hypertrophy in black vs. white heart transplant patients 1 year after surgery. Ethn Dis 1 (1991) 1335-1341
14. Goodroe R., Bonnema D.D., Lunsford S., et al. Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant 26 (2007) 145-151
15. Ventura H.O., Mehra M.R., Stapleton D.D., and Smart F.W. Cyclosporine-induced hypertension in cardiac transplantation. Med Clin North Am 81 (1997) 1347-1357
16. Brilla C.G., Funck R.C., and Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102 (2000) 1388-1393
17. Schmieder R.E., Martus P., and Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275 (1996) 1507-1513
18. Okin P.M., Devereux R.B., Jern S., et al., Losartan Intervention for Endpoint reduction in Hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 108 (2003) 684-690
19. Midtvedt K., Ihlen H., Hartmann A., et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 72 (2001) 107-111
20. Harrap S.B., and O'Sullivan J.B. Cardiac transplantation, perindopril, and left ventricular hypertrophy in spontaneously hypertensive rats. Hypertension 28 (1996) 622-626
21. Angermann C.E., Spes C.H., Willems S., Dominiak P., Kemkes B.M., and Theisen K. Regression of left ventricular hypertrophy in hypertensive heart transplant recipients treated with enalapril, furosemide, and verapamil. Circulation 84 (1991) 583-593
22. Saghir M., Areces M., and Makan M. Strain rate imaging differentiates hypertensive cardiac hypertrophy from physiologic cardiac hypertrophy (athlete's heart). J Am Soc Echocardiogr 20 (2007) 151-157